Acceptability of multipurpose human papillomavirus vaccines among providers and mothers of adolescent girls: A mixed-methods study in five countries by Vielot, Nadja A. et al.
Contents lists available at ScienceDirect
Papillomavirus Research
journal homepage: www.elsevier.com/locate/pvr
Acceptability of multipurpose human papillomavirus vaccines among
providers and mothers of adolescent girls: A mixed-methods study
in ﬁve countries
Nadja A. Vielota,⁎, Shoshana K. Goldberga, Gregory Zimetb, Sara B. Smitha, Mary Anne
McDonaldc, Silvina Ramosd, Karen Morgane,f, Chan Joo Kimg, Karin L. Richterh, Merce Perisi,
Kevin J. Whaleyj, Jennifer S. Smitha,k
a Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, CB#
7435, Chapel Hill, NC 27599, USA
b Section of Adolescent Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
c Center on Genomics, Race, Identity, Diﬀerence (GRID), Duke University, Durham, NC, USA
d Centro de Estudios de Estado y Sociedad, Buenos Aires, Argentina
e Perdana University, Royal College of Surgeons in Ireland School of Medicine, Kuala Lumpur, Malaysia
f Royal College of Surgeons in Ireland, Dublin, Ireland, UK
g Department of Obstetrics and Gynecology, The Catholic University of Korea, Medical College, St Paul's Hospital, Seoul, Korea
h Department of Medical Virology, University of Pretoria and National Health Laboratory Services, Pretoria, South Africa
i Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d′Oncologia, Barcelona, Spain
j Mapp Biopharmaceutical, Inc., San Diego, CA, USA
k UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
A R T I C L E I N F O
Keywords:
Vaccines
Acceptability
Multipurpose
Human papillomavirus
Sexually transmitted infections
Adolescents
A B S T R A C T
Introduction: Multipurpose vaccines (MPVs) could be formulated to prevent multiple sexually transmitted
infections simultaneously. Little is known about acceptability of MPVs among vaccine health care providers
(HCPs) or mothers of adolescent girls.
Methods: 151 adolescent vaccine providers and 118 mothers of adolescent girls aged 9–14 were recruited from
ﬁve geographically-diverse countries: Argentina, Malaysia, South Africa, South Korea, and Spain. We assessed
providers’ preferences for single-purpose human papillomavirus (HPV) vaccine versus MPVs (including HPV
+herpes simplex virus (HSV)−2, HPV+HIV, or HPV+HSV-2+HIV) via quantitative surveys. Maternal MPV
attitudes were assessed in four focus group discussions (FGDs) in each country.
Results: Most providers preferred MPVs over single-purpose HPV vaccination, with preference ranging from
61% in Malaysia to 96% in South Africa. HPV+HSV-2+HIV was the most preferred MPV formulation (56–82%).
Overall, 53% of the mothers preferred MPVs over single-purpose HPV vaccines, with strongest support in South
Africa (90%) and lowest support in South Korea (29%). Convenience and trust in the health care system were
commonly-cited reasons for MPV acceptability. Safety and eﬃcacy concerns were common barriers to accepting
MPVs, though speciﬁc concerns diﬀered by country. Across FGDs, additional safety and eﬃcacy information on
MPVs were requested, particularly from trusted sources like HCPs.
Conclusions: Though maternal acceptability of MPVs varied by country, MPV acceptability would be enhanced
by having HCPs provide parents with additional MPV vaccine safety and eﬃcacy information. While most
providers preferred MPVs, future health behavior research should identify acceptability barriers, and targeted
provider interventions should equip providers to improve vaccination discussions with parents.
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1. Introduction
Sexually-transmitted infections (STIs) can have severe long-term
eﬀects on sexual and reproductive health. Herpes simplex virus (HSV-
2) and human immunodeﬁciency virus (HIV) contribute to high global
morbidity, and cannot be cured or prevented by prophylactic vaccina-
tion. Research on HSV-2 and HIV preventive technologies is underway,
and the Multipurpose Technology Working Group has prioritized the
development of technologies to prevent both infections simultaneously
[1]. We therefore posit that multipurpose technologies could be
eﬀective for STI/HIV prevention in adolescents, conferring STI/HIV
protection before sexual debut.
Prophylactic multipurpose vaccines (MPVs) could reduce accept-
ability and adherence barriers to STI/HIV prevention. One of the ﬁrst
MPVs was licensed in the United States in 1948 against diphtheria,
tetanus, and pertussis [2]. By 2015, diphtheria-tetanus-acellular per-
tussis (Tdap) vaccination exceeded 80% in the United States, largely
controlling these high-morbidity infections and demonstrating that
MPVs can be acceptable to caregivers [3].
Human papillomavirus (HPV) is one of the only vaccine-preventable
STIs. HPV vaccines are highly-eﬃcacious against high-grade cervical
lesions – which are associated with cervical, vaginal, vulvar, and anal
cancers – caused by high-risk HPV types [4]. Given the high global
priority of preventing HPV-associated cancers, HPV vaccines were
licensed in over 100 countries and integrated into 87 countries’ national
vaccination programs by November 2016 [5]. HPV vaccines could serve as
the basis for an MPV to prevent multiple STIs, including HSV-2 and HIV.
To date, no such MPVs have been developed, nor have any
published studies explored the acceptability of MPVs for STIs/HIV. It
remains unknown whether providers would administer MPVs, or
whether parents of adolescents would accept them, presenting a
potential barrier to future MPV program implementation.
To assess the acceptability of hypothetical MPVs for STI/HIV
prevention, we conducted a mixed-methods study among adolescent
vaccine providers and mothers of adolescent girls in ﬁve geographi-
cally-diverse countries. We hypothesized that MPV preference would
be high among providers [6–12] and mixed among mothers, based on
barriers reported in the HPV vaccine literature [13–17]. To our
knowledge, this is the ﬁrst study to assess providers’ and mothers’
attitudes toward MPVs, providing insight into the acceptability of
MPVs as a strategy to promote sexual health in adolescents.
2. Methods
2.1. Study participants
2.1.1. Providers (Quantitative)
Providers from Argentina, Malaysia, South Africa, South Korea and
Spain were identiﬁed via non-probability convenience sampling and
recruited through mail, email, phone, or in-person. Eligible providers
were authorized to administer adolescent vaccines per each country's
medical regulations.
2.1.2. Mothers (Qualitative)
Between November 2013 and April 2014, each country conducted
four focus group discussions (FGDs). Mothers were recruited using
non-probability convenience sampling from medical oﬃces, health
centers, or schools. Eligible mothers had a daughter old enough to
receive HPV vaccination, based on each country's vaccination guide-
lines at the time of data collection (minimum age: South Africa=9;
Argentina/South Korea/Spain=11; Malaysia=13). Participating
mothers were assigned to FGDs based on whether their daughters
had received HPV vaccination. In Spain, six mothers of unvaccinated
daughters completed in-depth interviews rather than FGDs. To ensure
comparability of the ﬁndings across countries, this analysis reports
ﬁndings from FGDs only.
In-country institutional review boards (IRB) approved this study
prior to data collection. University of North Carolina (UNC) study staﬀ
received IRB approval for analysis of de-identiﬁed secondary data.
2.2. Measures
2.2.1. Providers (Quantitative)
Providers’ demographic information and attitudes towards single-
purpose HPV vaccine and MPVs were collected by a study interviewer
trained in structured interviewing techniques. Two questions assessed MPV
attitudes: 1) “MPVs in the future may protect against HPV plus other
infections, such as HSV-2 or HIV. Which would you prefer to recommend
to girls and their parents: A vaccine for HPV alone, or anMPV?”; 2) “If an
MPV were available, which would you be most likely to recommend: HPV
+HSV-2; HPV+ HIV; or HPV+HSV-2+HIV?” Providers were allowed to
answer “No preference” or “Would not recommend MPV”.
2.2.2. Mothers (Qualitative)
Each FGD followed a semi-structured discussion guide that as-
sessed mothers’ attitudes towards various aspects of adolescent HPV
vaccination; the present analysis involves discussions around MPVs.
Discussion moderators gave prompts from the discussion guide, and
additional questions emerged through probing and clarifying state-
ments (Appendix A). Although HPV vaccines are approved for girls and
boys, this study focused on vaccination for girls in keeping with local
HPV vaccination recommendations [18–21].
2.3. Analysis
2.3.1. Providers (Quantitative)
In-country staﬀ double-entered de-identiﬁed data into English
language EpiData forms, and translated data into English when
necessary. Data were cleaned and analyzed at UNC, the central
coordinating site. Univariate tabulations were performed in SAS 9.4
(SAS Institute Inc., Cary, NC).
2.3.2. Mothers (Qualitative)
In-country researchers facilitated the verbatim transcription of
FDG recordings and their translation to English. Translations were
reviewed by in-country study staﬀ who were native speakers of the
language used in the FGDs and ﬂuent in English. UNC study staﬀ
reviewed the translations for meaning, and clariﬁed colloquial usages,
local references, and cultural contexts with the lead in-country
researchers before analysis, and during analysis as needed.
Cleaned transcripts were entered into ATLAS.ti (ver. 7, Berlin,
Germany) for thematic content coding. An experienced qualitative
researcher supervised data management and analysis. An initial codebook
was developed based on themes outlined in the FGD script, and additional
codes were added iteratively as they emerged from the data [22]. One
transcript from each country was reviewed and coded independently by two
research assistants using initial and additional codes; coded transcripts
were then compared, and inconsistent coding decisions were discussed and
reconciled [23]. Additional codes were incorporated into the existing
codebook, and remaining transcripts were coded using the same
procedure. Qualitative data are summarized by commonly-cited themes.
3. Results
3.1. Providers (Quantitative analysis)
3.1.1. Providers' medical practices
Of 353 providers contacted, 151 were enrolled between October
2013 and April 2014 across the ﬁve countries (Argentina [n=30];
Malaysia [n=30]; South Africa [n=31]; South Korea [n=30]; and Spain
[n=30]). Providers were primarily family physicians and general
practitioners (31.1%), obstetrician-gynecologists (25.8%), and pedia-
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tricians (21.9%) who provided vaccine services principally in clinics
(80.1%) and private facilities (53.6%) (Table A1).
All providers from Argentina (100%), and most from Spain (86.7%)
and Malaysia (76.7%), had ever provided HPV vaccine to adolescents,
compared with half in South Korea (50.0%) and one-third in South
Africa (35.5%) (Table A2). Overall, most (57.4%) providers preferred to
administer HPV vaccine concomitantly with other vaccines (e.g.,
hepatitis A/B, inﬂuenza, tetanus-diphtheria-pertussis), though prefer-
ence for concomitant administration varied across countries ( > 75% in
Argentina and Spain vs. 16.0% in South Korea) (Table A2).
3.1.2. Providers' attitudes towards MPVs
Providers’ preference for MPVs over single-purpose HPV vaccine
was high (82.3% overall), from 60.7% in Malaysia to 96.0% in South
Africa. Among 107 providers who preferred MPVs, a formulation
including HPV, HSV-2, and HIV was the most highly-preferred
(56.0–81.5%) in all countries (Fig. 1). One Spanish provider preferred
vaccination against HSV-2+HIV only (3.6%), and two Argentinian
providers hesitated to recommend MPVs in general (7.4%).
3.2. Mothers (Qualitative analysis)
3.2.1. Mothers' overall attitudes towards MPVs
A total of 118 mothers (70 with vaccinated daughters, 48 with
unvaccinated daughters) were enrolled across ﬁve countries (Argentina
[n=23]; Malaysia [n=26]; South Africa [n=21]; South Korea [n=31];
and Spain [n=17]), with a median 5.5 participants per group.
Malaysian mothers had the highest proportion of vaccinated daughters
(80.7%), and South Korea had the lowest proportion (25.8%) (Table
A1). Half of mothers (52.5%, n=62) stated a preference for MPVs; MPV
preference was highest in South Africa (90.5%, n=19) and lowest in
South Korea (29.0%, n=8) (Table A3). MPV support was slightly higher
among mothers of vaccinated girls (55.7%, n=39) than unvaccinated
girls (47.9%, n=23), though notable diﬀerences emerged by country
(Table A3). In South Korea and Malaysia, MPV support was higher
among mothers of vaccinated girls than unvaccinated girls, (South
Korea: 37.5% [3/8] vs. 26.1% [6/23]; Malaysia: 71.4% [15/21] vs.
0.0% [0/5]), whereas in Argentina and South Africa, mothers of
unvaccinated girls were more likely to support MPVs over single-
purpose vaccines (Argentina: 47.1% [8/17] vs. 50.0% [3/6]; South
Africa: 71.4% [5/7] vs. 100% [14/14]).
Mothers’ perceived advantages and disadvantages of MPVs emerged
from the FGDs along several cross-country themes, detailed below. We also
observed variation in MPV perceptions by country (Table A3).
3.2.2. Perceived advantages of MPVs
3.2.2.1. Convenience. Across all countries, 23 mothers (n=11 [15.7%]
vaccinated; n=12 [25%] unvaccinated) perceived MPVs to be more
convenient than single-purpose vaccines. Mothers noted that it was
“good to just get it over with at once” (South Korea, unvaccinated), and
appreciated that with “one shot, it is ﬁnished” (Malaysia, vaccinated).
Others framed convenience in terms of health beneﬁts, preferring
MPVs for conferring “two for one” (Spain, vaccinated) multi-disease
immunity and their ability to “kill ten-thousand birds with one stone”
(Argentina, vaccinated).
3.2.2.2. Addresses teenage risk. Eighteen mothers (n=14 [20%]
vaccinated; n=4 [8.3%] unvaccinated) reported that MPVs would
protect their adolescent daughters once they inevitably engaged in
sexual behavior.
“[Sex] is one thing that we cannot stop our kids from doing…They
like experimenting…So at least if they can be protected, why not
[vaccinate]?” (South Africa, vaccinated).
3.2.2.3. Trust in vaccine development. Eleven mothers (n=7 [10%]
vaccinated; n=4 [8.3%] unvaccinated) across all countries trusted
pharmaceutical companies to develop safe and eﬀective vaccines,
believing that they “probably have done some research somewhere
and are sure of immunity up to this point” (South Africa, vaccinated).
Conﬁdence in vaccine development often translated to general comfort
with vaccines. One mother was unconcerned with potential side eﬀects,
as “studies are done at a national level and it is decided that there is a
high enough number of cases to determine [support for] a vaccine.”
(Spain, vaccinated).
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3.2.3. Perceived barriers to MPVs
3.2.3.1. Side eﬀects. Fear of potential MPV side eﬀects was the most
commonly-reported concern (n=12 [17.1%] vaccinated; n=14 [29.2%]
unvaccinated), often described in non-speciﬁc language: “side eﬀects”;
“something bad.” Mothers of unvaccinated girls were generally more
concerned about side eﬀects:
“I’m hesitating because of the side eﬀects but there isn’t any
information on that.” (South Korea, unvaccinated).
Conversely, mothers of vaccinated girls viewed side eﬀects as just
one piece of information needed: ‘It's also interesting to know about
the side eﬀects, if there are any.” (Argentina, vaccinated).
3.2.3.2. Strength of the vaccine. Across all countries, 15 mothers
(n=11 [15.7%] vaccinated; n=4 [8.3%] unvaccinated) expressed
concern that combining multiple vaccines would make MPVs too
strong to be safe. These mothers felt that MPVs were “too much for
just one time” (Argentina, vaccinated), increasing the risk of side
eﬀects. Conversely, 12 mothers (10 [14.3%] vaccinated; 2 [4.2%]
unvaccinated) mothers feared that MPVs would be weaker than a
single-purpose vaccine, believing that they would be either too non-
speciﬁc to have an eﬀect, or would not be fully-eﬃcacious against all
infections:
It being a general vaccine, is it really going to be protecting the
child? (South Africa, vaccinated).
Multipurpose doesn’t concentrate on one kind. The eﬀect of each
[vaccine] can be mixed, diluted, or toxic when you use all together. It's
like having 70% for each rather than 90% for one…. (South Korea,
unvaccinated).
3.2.3.3. Mistrust of pharmaceutical companies. Seven mothers (n=3
[4.3%] vaccinated; n=4 [8.3%] unvaccinated) in Argentina, Malaysia,
and South Korea cited mistrust in the pharmaceutical industry,
believing that they had “economic interests there” (Argentina,
vaccinated). Mothers also suspected that pharmaceutical companies
wanted to experiment on their daughters, that MPVs would be of poor
quality, or that MPVs would be developed for provider/pharmaceutical
convenience rather than for health beneﬁts.
3.2.4. Information needed to accept MPVs
When probed on the additional information they would need to
accept MPVs, mothers requested information along several major
themes.
Safety information, such as anticipated side eﬀects, was most
commonly requested: “If it's preventive and more clinical results
and side eﬀects become clear, then I’ll consider it” (South Korea,
unvaccinated). This led nine (9) mothers across three countries to
prefer to “wait and see” (Malaysia, unvaccinated) how others re-
sponded to MPVs, and/or for MPV uptake to become more widespread,
before accepting MPVs.
Process information included logistical issues such as the target
population, vaccination requirements, and who would administer
vaccines:
… I don’t know if it is going to be done in all the areas and all the
regions…with the 9–14 [year olds]. I would prefer that [MPVs] be
taken over all the schools. (South Africa, vaccinated).
Vaccination literacy reﬂected low perceived health knowledge.
These mothers were confused about HPV infection and the concept
of MPVs: “What is papillomavirus, then why does it aﬀect the uterus?”
(Spain, vaccinated); “It's too scientiﬁc. Like I don’t understand the
word multivalent” (Argentina, unvaccinated). Many mothers called for
widespread information dissemination through “media…or television”,
“drug company…brochures”, or “talks at school, for the parents and
the kids” to increase their vaccine literacy.
Most commonly, mothers desired information from a trusted
source to make a ﬁnal decision. For these mothers, the established
relationship with “the family doctor in your area, the one you go to,
who knows you” (Argentina, unvaccinated) instilled a unique trust in
their providers:
I don't trust everything on the internet, so everybody still needs to
ﬁnd that family [general practitioner] that you trust, just to check….
(Malaysia, vaccinated).
Others were less concerned with the source, desiring only that
information come from trustworthy “public associations…say,
Ministry of Health.” (South Korea, unvaccinated).
4. Discussion
This mixed-methods study demonstrated acceptability of MPVs to
protect against HPV and STIs/HIV among providers in ﬁve countries.
Most providers preferred MPVs to HPV vaccination alone, and
providers also expressed the strongest preference for an MPV that
prevents multiple STIs (HPV, HSV-2, and HIV). MPV support was
lower among mothers than providers; half of mothers preferred MPVs
to single purpose vaccines, though notable variation emerged by
country and daughter's vaccination status.
Mothers who preferred MPVs cited convenience, a need for STI
prevention, and conﬁdence in the safety and eﬃcacy of approved
vaccines. Yet, support for MPVs among some mothers was tentative,
even among those who preferred them to single-purpose HPV vaccines.
Mothers from all countries expressed potential concerns, including the
eﬃcacy of individual vaccine components; increased side eﬀects;
reticence to accept a new drug; and suspicion of pharmaceutical
companies. Concerns regarding safety and overloading of the immune
system are consistent with ﬁndings from research on parental attitudes
toward existing combination childhood vaccines, such as measles-
mumps-rubella and Tdap [24,25].
Evidence from the HPV vaccine literature may help explain lower
maternal MPV acceptability, as well as between-country diﬀerences in MPV
acceptability. Provider and maternal preference for MPVs was highest in
South Africa (96% and 91%, respectively), reﬂecting high HPV vaccine
acceptability by providers in prior studies in Sub-Saharan Africa [26,27]. In
a qualitative study of HPV vaccine acceptability among 39 adolescent-
caregiver dyads in Soweto, South Africa, mothers considered HPV vaccina-
tion a solution to a perceived inability to protect their daughters from STIs
[28]. Mothers also discussed the importance of STI/HPV prevention given
South Africa's HIV epidemic [28], paralleling themes that emerged in our
own sample. Conversely, MPV support was lower in South Korea (29%)
than in all other countries. In this study, South Korean mothers were
unique in citing ﬁnancial barriers to MPV acceptability, potentially because
a nationally-funded HPV vaccination program did not exist at the time of
data collection; this program began June 2016 [29,30]. Previous studies of
HPV vaccine acceptability among South Korean adults and mothers have
consistently found that cost was a barrier to HPV vaccine acceptability [31–
33], suggesting that future vaccination programs address the ﬁnancial
implications of MPVs.
A limitation of this study is the focus on MPV acceptability without
assessing acceptability of individual HIV and HSV-2 vaccines.
However, prior studies have shown acceptability of HIV and HSV-2
vaccines from providers, policy-makers, and community members
globally [34–38]. This study also focused on vaccination in girls, based
on the countries’ HPV vaccination recommendations at the time of data
collection. While gender-neutral vaccination policies can protect boys
from STIs and harmful sequelae, and prevent transmission to girls,
low- and middle-income countries tend to prioritize vaccination in girls
to maximize the cost-eﬀectiveness of HPV vaccination [39]. Small
sample sizes of providers and mothers limit the generalizability of the
ﬁndings within study countries, and preclude the use of statistical tests
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to assess group diﬀerences between mothers of vaccinated and
unvaccinated daughters. Convenience sampling of mothers similarly
limits generalizability; mothers were recruited primarily from urban
settings, and may not represent the diverse populations of their
countries. Further, the interview guide contained more prompts
regarding MPV concerns than advantages. Thus, it is unclear if the
many reports of concerns reﬂect true discomfort with MPVs, or are
simply the result of heavy focus on concerns in the FGDs. Finally, some
mothers did not actively participate in discussions, resulting in low
response rates to certain prompts.
Findings from this mixed-methods study oﬀer key information to guide
the development and roll-out of future MPVs. Our inclusion of ﬁve
geographically-diverse countries furthers understanding of similarities
and diﬀerences in MPV perceptions across cultures. Including mothers of
vaccinated and unvaccinated girls oﬀers perspectives on local patterns of
HPV vaccination that may be considered in developing future MPV
programs. By including both providers and mothers, we triangulated
vaccination attitudes and potential acceptability barriers from the two
sources most inﬂuential in adolescent vaccination. Regardless of vaccine
preference, mothers desired additional information from a known health-
care provider about side eﬀects and eﬃcacy before accepting MPVs. This
corroborates ﬁndings from prior studies indicating that a provider's
recommendation is the most important predictor of adolescent vaccination,
and emphasizes the need to intervene with providers and caregivers to
promote adolescent vaccination [40,41].
5. Conclusions
Providers and mothers of adolescent girls reported generally high
acceptability of hypothetical MPVs to prevent STIs/HIV, provided that
safety and eﬃcacy are demonstrated in clinical trials. Educating healthcare
providers on concise, eﬀective approaches to MPV communication could
enhance acceptability of potentially life-saving vaccines. Near-term research
should develop culturally-tailored information about emerging MPVs that
anticipates and addresses caregivers’ concerns. Global ﬁnancial and political
commitment will be needed to develop and promote MPVs, particularly to
vulnerable populations in resource-limited settings.
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Appendix A. Discussion guide for multipurpose vaccine acceptability among mothers of adolescent girls
[Discussion leader reads].
“Multipurpose vaccines protect against more than one type of infection or illness. Researchers are working on new multipurpose vaccines
against HPV plus another infection. Some of these multipurpose HPV vaccines protect against HPV plus illnesses like Herpes, which can cause sores
in the genital area; Hepatitis B, which can cause liver damage; or HIV, which causes the immune system to stop working.
“What do you think about a multipurpose HPV vaccine?”
Follow-up questions:
• (If daughter is currently unvaccinated against HPV) Which would you prefer for your daughter: a vaccine for HPV alone or a multipurpose
vaccine?
• (If daughter is currently vaccinated against HPV) If you had another daughter who was not yet vaccinated, which would you prefer: a vaccine for
HPV alone or a multipurpose vaccine?
• What are some reasons for this?
• Which other infections would you want this vaccine to protect your daughter against?
• Do you have any concerns or worries about a multipurpose HPV vaccine?
• If so, what concerns or worries do you have?
• What kind of information would you need to help you to feel less worried about a multipurpose vaccine?
See Appendix Tables A1–A3.
Table A1
Descriptive characteristics of adolescent vaccine providers and mothers of daughters in five countries.
Adolescent vaccine providers (n=151)
Argentina (n = 30) Malaysia (n = 30) South Africa (n = 31) South Korea (n = 30) Spain (n = 30) Overall (n =
151)
Dates of interviews Feb-Mar 2014 Nov-Dec 2013 Feb-Mar 2014 Nov 2013-Jan 2014 Dec 2013-Apr 2014 Nov 2013-Apr
2014
Provider catchmentarea San Luis Province Putrajayac Pretoria Seoul Hospitalet de Llobregate –
Olivos and Vicente
Lópeza
Granollerse
Incheon Sabadelle
City of Rosariob Selangor state Mamelodi Llavanerese
(continued on next page)
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Table A1 (continued)
Adolescent vaccine providers (n=151)
Argentina (n = 30) Malaysia (n = 30) South Africa (n = 31) South Korea (n = 30) Spain (n = 30) Overall (n =
151)
Dates of interviews Feb-Mar 2014 Nov-Dec 2013 Feb-Mar 2014 Nov 2013-Jan 2014 Dec 2013-Apr 2014 Nov 2013-Apr
2014
City of San Lorenzob Esplugues de
Llobregate
Bundang, Bucheon
CerdanyolaeCity of San Genarob Kuala Lumpurc Atteridgevilled Reusf
Ilsan Gerona City of Buenos Aires
Puigcerdàg
La Pobla de Segurh
Type of provider
Family/internal medicine, general
practice
5 (16.7%) 26 (86.7%) 8 (25.8%) 6 (20%) 2 (6.6%) 47 (31.1%)
Midwife – – 2 (6.5%) – 7 (23.3%) 9 (6%)
Nurse/nurse practitioner – 3 (10.0%) 10 (32.3%) – 4 (13.3%) 17 (11.3%)
OB/GYN 12 (40.0%) 2 (6.7%) 7 (22.6%) 12 (40%) 6 (20%) 39 (25.8%)
Pediatrician 13 (43.3%) 1 (3.3%) – 12 (40%) 7 (23.3%) 33 (21.9%)
Pharmacist – – 2 (6.5%) – – 2 (1.3%)
Preventive physician – – – – 4 (13.3%) 4 (2.6%)
Health promoter – – 2 (6.5%) – – 2 (1.3%)
Place of vaccine provision
Clinic 25 (83.3%) 28 (93.3%) 16 (51.6%) 28 (93.3%) 24 (80%) 121 (80.1%)
School – 1 (3.3%) 5 (16.1%) – 3 (10%) 9 (6.0%)
Hospital 12 (40.0%) 1 (3.3%) 15 (48.4%) 2 (6.7%) 8 (26.7%) 38 (25.2%)
Health NGO/Pharmacy – – 2 (6.45%) – – 2 (1.3%)
Type of vaccine provision
Public only 4 (13%) – 17 (54.8%) – 22 (73.3%) 43 (28.5%)
Private only 11 (36.7%) 28 (93.3%) 11 (35.5%) 30 (100%) 1 (3.3%) 81 (53.6%)
Both 15 (50.0%) 1 (3.3%) 3 (9.7%) – 7 (23.3%) 26 (17.2%)
Mothers of daughters (n=118)
Argentina (n = 23) Malaysia (n = 26) South Africa (n = 21) South Korea (n = 31) Spain (n = 23) Overall (n =
118)
Date Feb-Mar 2014 Jan-Apr 2014 Nov-Dec 2013 Dec 2013-Jan 2014 Dec 2013-Apr 2014 Nov 2013-Apr
2014
Location
-FGD 1 Buenos Aires (n=5) Kuala Lumpur
(n=5)
Atteridgeville (n=6) Seoul (n=8) Barcelona (n=6)
-FGD 2 San Isidroa (n=7) Kuala Lumpur
(n=11)
Kwaggasrandd (n=4) Seoul (n=8) Sabadell (n=5)
-FGD 3 San Isidroa (n=6) Johor Bahru (n=5) Prinshof (n=3) i Seoul (n=8) Montcada (n=4)
-FGD 4 Vicente Lópeza (n=5) Selangor (n=5) Kwaggasrand (n=8) i Gyeonggi-do (n=7) Mataró (n=2)
Daughters vaccinated against
HPV
17 (73.9%) 21 (80.7%) 7 (33.3%) 8 (25.8%) 17 (73.9%) 70 (59.3%)
Daughters unvaccinated
against HPV
6 (26.1%) 5 (19.2%) 14 (66.7%) 23 (74.2%) 6 (26.1%)j 48 (40.7%)
OB/GYN=obstetrician/gynecologist; FGD=focus group discussion; HPV=human papillomavirus
a Buenos Aires Province;
b Santa Fe Province;
c Wilayah;
d township outside of Pretoria;
e Barcelona Province;
f Tarragona Province;
g Gerona Province;
h Lérida Province;
Table A2
Adolescent vaccine practices and attitudes among providers in five countries.
Ever provided HPV vaccine to
adolescents 9–14 years
Preference for concomitant administration of HPV and
other adolescent vaccinesa
Preference for MPVs over single-
purpose HPV vaccine
Country N n (%) N n (%) N N (%)
Argentina 30 30 (100.0%) 26 20 (76.9%) 24 22 (91.7%)
Malaysia 30 23 (76.7%) 27 15 (55.6%) 28 17 (60.7%)
South Africa 31 11 (35.5%) 24 14 (58.3%) 25 24 (96.0%)
South Korea 30 15 (50.0%) 25 4 (16.0%) 28 22 (78.6%)
Spain 30 26 (86.7%) 27 21 (77.8%) 25 22 (88.0%)
Totalb 151 105 (69.5%) 129 74 (57.4%) 130 107 (82.3%)
a Including meningococcal, tetanus-diphtheria-pertussis, inﬂuenza, and Hepatitis A/B.
b Denominator for preference questions does not add to 151 owing to missing/invalid responses (N=22 missing responses for concomitant administration; N=21 missing responses
for MPV preference)
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